(NASDAQ: SKYE) Skye Bioscience's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.52%.
Skye Bioscience's earnings in 2026 is -$50,492,578.On average, 7 Wall Street analysts forecast SKYE's earnings for 2026 to be -$30,439,394, with the lowest SKYE earnings forecast at -$48,251,053, and the highest SKYE earnings forecast at -$21,943,567. On average, 7 Wall Street analysts forecast SKYE's earnings for 2027 to be -$32,227,733, with the lowest SKYE earnings forecast at -$46,862,533, and the highest SKYE earnings forecast at -$21,199,717.
In 2028, SKYE is forecast to generate -$42,633,216 in earnings, with the lowest earnings forecast at -$53,458,001 and the highest earnings forecast at -$23,059,342.